The extraordinarily high toxicity of botulinum neurotoxins primarily results from their specific binding and uptake into neurons. At motor neurons, the seven BoNT (botulinum neurotoxin) serotypes A-G inhibit acetylcholine release leading to flaccid paralysis. Uptake of BoNT/A, B, E, F and G requires a dual interaction with gangliosides and the synaptic vesicle proteins synaptotagmin or SV2 (synaptic vesicle glycoprotein 2), whereas little is known about the cell entry mechanisms of the serotypes C and D, which display the lowest amino acid sequence identity compared with the other five serotypes. In the present study we demonstrate that the neurotoxicity of BoNT/D depends on the presence of gangliosides by employing phrenic nerve hemidiaphragm preparations derived from mice expressing the gangliosides GM3, GM2, GM1 and GD1a, or only GM3 [a description of our use of ganglioside nomenclature is given in Svennerholm (1994) Prog. Brain Res. 101, XI-XIV]. High-resolution crystal structures of the 50 kDa cell-binding domain of BoNT/D alone and in complex with sialic acid, as well as biological analyses of single-site BoNT/D mutants identified two carbohydrate-binding sites. One site is located at a position previously identified in BoNT/A, B, E, F and G, but is lacking the conserved SXWY motif. The other site, co-ordinating one molecule of sialic acid, resembles the second ganglioside-binding pocket (the sialic-acid-binding site) of TeNT (tetanus neurotoxin).

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20101042DOI Listing

Publication Analysis

Top Keywords

botulinum neurotoxin
8
carbohydrate-binding sites
8
synaptic vesicle
8
sialic acid
8
neurotoxin serotype
4
serotype attacks
4
attacks neurons
4
neurons carbohydrate-binding
4
sites ganglioside-dependent
4
ganglioside-dependent manner
4

Similar Publications

Background: Spasticity is an upper motor neuron syndrome that exacerbates motor paralysis and is rarely associated with pain. This report elucidates the management of drug-resistant pain attributed to an adolescent brain tumor using botulinum therapy.

Case Presentation: A 15-year-old female patient experienced dizziness, developed muscle weakness in her upper extremities, and was diagnosed with diffuse glioblastoma of the pons.

View Article and Find Full Text PDF

Objectives: To evaluate the cost-utility of botulinum toxin A (BoNT-A) for treating upper limb (UL) and lower limb (LL) post-stroke spasticity.

Design: Using a Markov model, adopting a societal perspective and a lifetime horizon with a 3% annual discount rate, the cost-utility analysis was conducted to compare BoNT-A combined with standard of care (SoC) with SoC alone. Costs, utilities, transitional probabilities and treatment efficacy were derived from 5-year retrospective data from tertiary hospitals and meta-analysis.

View Article and Find Full Text PDF

Background: Botulinum toxin is a well-established treatment for dynamic glabellar lines. Glabellar contraction patterns were described previously in the general Brazilian population and also among Koreans, Chinese, and Indian individuals. So far, no study has addressed glabellar contraction "patterns" in Black subjects.

View Article and Find Full Text PDF

Purpose Of Review: This narrative review aims to report upon the existing treatment evidence and strategies for managing lower urinary tract symptoms (LUTS) during treatment, including transurethral resection and intravesical therapy. This review also attempts to examine novel approaches to mitigate treatment-related lower urinary tract symptoms and improve treatment adherence.

Recent Findings: There is sparse but promising evidence in improving LUTS secondary to intravesical therapy.

View Article and Find Full Text PDF

Injections of Botulinic Neuroprotein Combined with Low Molecular Weight Hyaluronic Acid and Cluster of Lyophilized Amino Acids in One Syringe.

J Clin Aesthet Dermatol

December 2024

Dr. Mathey is with the International Master Course on Aging Science in Paris, France.

Background: Intradermal injections of highly diluted botulinic neuroprotein is a popular aesthetic medicine procedure to improve the texture of the skin, enlarged pores, and fine lines.

Objective: The authors present a case report of nine subjects who received treatment with botulinic neuroprotein combined with an amino acid cluster and low molecular weight hyaluronic acid.

Methods: Nine women between the ages of 30 to 59 years old in a stable medical condition with moderate to severe lateral cantal wrinkles and smile lines at maximum expression and were recruited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!